FindTrial
Sign In

Visilizumab

DRUG12 trials

Sponsors

Stanford University, Fred Hutchinson Cancer Center, Facet Biotech, Abbott, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Acute Myeloid LeukemiaCrohn's DiseaseGraft Versus Host DiseaseGraft vs Host DiseaseGraft-vs-Host DiseaseImmunotherapyLymphomaRefractory Leukemia

Phase 1

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
CompletedNCT00032292
Facet BiotechGraft vs Host Disease
Start: 2002-03-31End: 2006-08-31Target: 34Updated: 2012-03-13
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
CompletedNCT00006009
Stanford UniversityLymphoma, Small Intestine Cancer
Start: 2001-04-30End: 2003-10-31Updated: 2013-05-15
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
CompletedNCT00267306
Facet BiotechSevere Ulcerative Colitis
Start: 2004-01-31End: 2006-12-31Target: 144Updated: 2012-03-09

Phase 2

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
NCT00032279
Fred Hutchinson Cancer CenterGraft-vs-Host Disease
Start: 2002-03-31Target: 80Updated: 2005-06-24
Research Study in Patients With Severe Ulcerative Colitis
CompletedNCT00032305
Facet BiotechUlcerative Colitis
Start: 2002-03-31End: 2005-11-30Target: 20Updated: 2012-03-07
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
CompletedNCT00267709
Facet BiotechCrohn's Disease
Start: 2005-02-28End: 2006-12-31Target: 18Updated: 2012-03-07
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
CompletedNCT00267722
Facet BiotechCrohn's Disease
Start: 2005-02-28End: 2006-12-31Target: 18Updated: 2012-03-07
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
TerminatedNCT00279435
Facet BiotechUlcerative Colitis
Start: 2006-08-31End: 2007-08-31Updated: 2012-03-12
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
TerminatedNCT00279422
Facet BiotechUlcerative Colitis
Start: 2006-02-28End: 2007-08-31Updated: 2012-03-12
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
TerminatedNCT00307827
AbbottUlcerative Colitis
Start: 2006-04-30End: 2007-11-30Updated: 2012-04-27
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
TerminatedNCT00720629
H. Lee Moffitt Cancer Center and Research InstituteGraft Versus Host Disease
Start: 2007-12-31End: 2013-12-31Updated: 2014-07-18

Phase 3

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
NCT04722952
The First Affiliated Hospital of Soochow UniversityAcute Myeloid Leukemia, Immunotherapy, Refractory Leukemia +1
Start: 2021-05-01End: 2024-01-01Target: 30Updated: 2021-12-03

Related Papers

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
2010-11-0159 citations
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease.
2009-02-2415 citations